High Court’s Myriad Ruling Will Spur Novel Patent Claims

Law360, New York (June 13, 2013, 10:17 PM EDT) -- The U.S. Supreme Court’s decision Thursday that isolated DNA cannot be patented is narrow enough that companies should still be able to find creative ways to draft their patent claims in order to protect discoveries involving human genes, attorneys say.

While it struck down patents held by Myriad Genetics Inc. covering isolated DNA associated with a higher risk of breast cancer, the high court said that synthetic DNA, methods of manipulating genes and other claims that involve more than just genes isolated from the human body...
To view the full article, register now.